Annexon Biosciences (ANNX) Price & Analysis

Compare

1,265 Followers

ANNX Stock Chart & Stats

Day’s Range― - ―

52-Week Range$1.29 - $7.85

Previous CloseN/A

Volume252.73K

Average Volume (3M)2.14M

Market Cap

$340.65M

Enterprise Value$156.58M

Total Cash (Recent Filing)$227.02M

Total Debt (Recent Filing)$27.63M

Price to Earnings (P/E)―

Beta2.00

Next Earnings

Nov 12, 2025

EPS Estimate

-0.34

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.34

Shares Outstanding109,886,620

10 Day Avg. Volume2,183,375

30 Day Avg. Volume2,136,332

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market Cap0.46

Enterprise Value/Revenue46.00

Enterprise Value/Gross Profit-160.43

Enterprise Value/Ebitda-0.79

Forecast

1Y Price Target

$11.60

Price Target Upside286.67% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering6

Bulls Say, Bears Say

Bulls Say

Clinical TrialsEarly completion of Phase 3 enrollment for the vonaprument (ANX007) program and entry into EMA’s PRIME PDC pilot increase the credibility of the 'vision preservation' label ambition.

Regulatory ApprovalThe EU-first pivot with an MAA in Q1 2026 is considered de-risked due to EMA's familiarity and prior deep dive.

Treatment AdvancementsTanruprubart's pivotal trial in GBS succeeded, demonstrating better outcomes for patients compared to traditional treatments.

Bears Say

Data TimelineProof-of-concept data from the oral complement inhibitor program ANX1502 is now anticipated by YE25 instead of mid-2025.

Financial ResourcesThe 2Q25 cash balance of $227M is sufficient into 2H26.

Regulatory ChallengesRegulatory talks still ongoing with FDA around requirements for the BLA submission of tanruprubart in Guillain-Barré Syndrome.

Annexon Biosciences News

Annexon participates in a conference call with JPMorgan

Conference call to address top 10 questions with management will be held on September 15 at 12:30 pm...

29d ago

ANNX

Annexon Biosciences Faces Financial Risks Amid Global Trade Challenges

Annexon Biosciences, Inc. (ANNX) has disclosed a new risk, in the Capital Markets category. Annexon Biosciences, Inc. faces...

2M ago

ANNX

Promising Outlook for Annexon Biosciences: Buy Rating Backed by Strong Pipeline and Financial Stability

In a report released today, Joseph Stringer from Needham maintained a Buy rating on Annexon Biosciences, with a...

2M ago

ANNX

Annexon Biosciences Reports Q2 2025 Financial Results

Annexon Biosciences, Inc. ( ($ANNX) ) has released its Q2 earnings. Here is a breakdown of the information...

2M ago

ANNX

Annexon reports Q2 EPS (34c), consensus (36c)

Cash and cash equivalents and short-term investments were $227M as of June 30. “We are well positioned to...

2M ago

ANNX

Annexon reports Q2 EPS (34c), consensus (36c)

The company’s cash and cash equivalents and short-term investments were $227M as of June 30. It said, “We...

2M ago

ANNX

Annexon completes enrollment in Phase 3 ARCHER II trial

Annexon (ANNX) announced complete enrollment of the Phase 3 ARCHER II trial of vonaprument for dry age-related macular...

3M ago

ANNX

Annexon tells Wells Fargo doctor tweet not factural

Wells Fargo analyst Derek Archila spoke to Annexon (ANNX) as the shares traded down earlier today post the...

3M ago

ANNX

Annexon Biosciences Holds Annual Stockholders Meeting

Annexon Biosciences ( ($ANNX) ) has issued an announcement. On June 5, 2025, Annexon, Inc. conducted its Annual...

4M ago

ANNX

Annexon Biosciences: Promising Pipeline and Strategic Developments Reinforce Buy Rating

Analyst Tazeen Ahmad of Bank of America Securities reiterated a Buy rating on Annexon Biosciences (ANNX – Research...

5M ago

ANNX

Annexon presents tanruprubart data at PNS annual meeting

Annexon (ANNX) presented oral and poster presentations highlighting improved outcomes with tanruprubart at the 2025 Peripheral Nerve Society...

5M ago

ANNX

Buy Rating on Annexon Biosciences: Promising ANX005 for GBS and Strategic Path to FDA Approval

Andrew Tsai, an analyst from Jefferies, maintained the Buy rating on Annexon Biosciences (ANNX – Research Report). The...

5M ago

ANNX

Annexon price target lowered to $14 from $20 at H.C. Wainwright

H.C. Wainwright lowered the firm’s price target on Annexon (ANNX) to $14 from $20 and keeps a Buy...

5M ago

ANNX

Annexon Biosciences: Promising Growth Potential with Key Catalysts and Strategic FDA Interactions

In a report released yesterday, Andrew Tsai from Jefferies maintained a Buy rating on Annexon Biosciences (ANNX –...

5M ago

ANNX

ANNX FAQ

What was Annexon Biosciences, Inc.’s price range in the past 12 months?

Annexon Biosciences, Inc. lowest stock price was $1.28 and its highest was $7.85 in the past 12 months.

What is Annexon Biosciences, Inc.’s market cap?

Annexon Biosciences, Inc.’s market cap is $340.65M.

When is Annexon Biosciences, Inc.’s upcoming earnings report date?

Annexon Biosciences, Inc.’s upcoming earnings report date is Nov 12, 2025 which is in 28 days.

How were Annexon Biosciences, Inc.’s earnings last quarter?

Annexon Biosciences, Inc. released its earnings results on Aug 14, 2025. The company reported -$0.34 earnings per share for the quarter, beating the consensus estimate of -$0.366 by $0.026.

Is Annexon Biosciences, Inc. overvalued?

According to Wall Street analysts Annexon Biosciences, Inc.’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Annexon Biosciences, Inc. pay dividends?

Annexon Biosciences, Inc. does not currently pay dividends.

What is Annexon Biosciences, Inc.’s EPS estimate?

Annexon Biosciences, Inc.’s EPS estimate is -0.34.

How many shares outstanding does Annexon Biosciences, Inc. have?

Annexon Biosciences, Inc. has 109,886,620 shares outstanding.

What happened to Annexon Biosciences, Inc.’s price movement after its last earnings report?

Annexon Biosciences, Inc. reported an EPS of -$0.34 in its last earnings report, beating expectations of -$0.366. Following the earnings report the stock price went up 2.521%.

Which hedge fund is a major shareholder of Annexon Biosciences, Inc.?

Currently, no hedge funds are holding shares in ANNX

Annexon Biosciences Stock Smart Score

Neutral

Fundamentals

Return on Equity

-66.75%

Trailing 12-Months

Asset Growth

-34.85%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Annexon Biosciences, Inc.

Annexon Biosciences (ANNX) is a clinical-stage biopharmaceutical company focused on developing novel therapies for patients with classical complement-mediated disorders. The company operates in the biotechnology sector and is dedicated to the development of innovative treatments that target the complement system, a part of the immune system, to address diseases across multiple therapeutic areas, including neurodegenerative and autoimmune disorders.

Annexon Biosciences (ANNX) Earnings & Revenues

Historic Earnings Reports

ANNX Stock 12 Month Forecast

Average Price Target

$11.60

▲(286.67% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"$0","15":"$15","3.75":"$3.75","7.5":"$7.5","11.25":"$11.25"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":14,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$14.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":11.6,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$11.60</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":9,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$9.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[0,3.75,7.5,11.25,15],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2024","6":"Jan<br/>2025","9":"May<br/>2025","12":"Sep<br/>2025","25":"Sep<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.07,2.9876923076923076,3.905384615384615,4.823076923076923,5.740769230769231,6.6584615384615375,7.576153846153845,8.493846153846153,9.411538461538461,10.329230769230769,11.246923076923077,12.164615384615384,13.082307692307692,{"y":14,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.07,2.803076923076923,3.536153846153846,4.269230769230769,5.002307692307692,5.735384615384615,6.468461538461538,7.201538461538462,7.934615384615384,8.667692307692308,9.40076923076923,10.133846153846154,10.866923076923078,{"y":11.6,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.07,2.603076923076923,3.136153846153846,3.6692307692307686,4.202307692307691,4.735384615384614,5.268461538461538,5.8015384615384615,6.334615384615384,6.867692307692307,7.40076923076923,7.933846153846153,8.466923076923075,{"y":9,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":4.75,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.83,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.1,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.11,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.28,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.27,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.13,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.64,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.81,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 6</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.86,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 6</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.47,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.45,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.07,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >